{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T14:52:49Z","timestamp":1785423169410,"version":"3.56.0"},"reference-count":65,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2016,9,9]],"date-time":"2016-09-09T00:00:00Z","timestamp":1473379200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Lizanell and Colbert Coldwell Foundation"},{"DOI":"10.13039\/100007131","name":"Texas Tech University","doi-asserted-by":"publisher","award":["Startup Funds"],"award-info":[{"award-number":["Startup Funds"]}],"id":[{"id":"10.13039\/100007131","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hoy Family Research"},{"name":"Anna Mae Doyle Gift Funds"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0162162","type":"journal-article","created":{"date-parts":[[2016,9,9]],"date-time":"2016-09-09T18:34:32Z","timestamp":1473446072000},"page":"e0162162","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":10,"title":["Preclinical Metabolism, Pharmacokinetics and In Vivo Analysis of New Blood-Brain-Barrier Penetrant Fingolimod Analogues: FTY720-C2 and FTY720-Mitoxy"],"prefix":"10.1371","volume":"11","author":[{"given":"Julius O.","family":"Enoru","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sesha","family":"Krishnamachari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Villanueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"DeMaio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adiba","family":"Watanyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh","family":"Chinnasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey B.","family":"Arterburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth G.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,9,9]]},"reference":[{"issue":"3","key":"ref1","doi-asserted-by":"crossref","first-page":"259","DOI":"10.31887\/DCNS.2004.6.3\/galexander","article-title":"Biology of Parkinson's disease: pathogenesis and pathophysiology of a multisystem neurodegenerative disorder","volume":"6","author":"GE Alexander","year":"2004","journal-title":"Dialogues Clin Neurosci"},{"issue":"5321","key":"ref2","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","article-title":"Mutation in the alpha-synuclein gene identified in families with Parkinson's disease","volume":"276","author":"MH Polymeropoulos","year":"1997","journal-title":"Science"},{"issue":"4","key":"ref3","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/ana.23894","article-title":"G51D alpha-synuclein mutation causes a novel Parkinsonian-pyramidal syndrome","volume":"73","author":"S Lesage","year":"2013","journal-title":"Annals of neurology"},{"issue":"9","key":"ref4","doi-asserted-by":"crossref","first-page":"2180 e1","DOI":"10.1016\/j.neurobiolaging.2014.03.024","article-title":"Novel alpha-synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson's disease-type pathology","volume":"35","author":"P Pasanen","year":"2014","journal-title":"Neurobiol Aging"},{"issue":"5646","key":"ref5","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1126\/science.1090278","article-title":"alpha-Synuclein locus triplication causes Parkinson's disease","volume":"302","author":"AB Singleton","year":"2003","journal-title":"Science"},{"issue":"9440","key":"ref6","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S0140-6736(04)17103-1","article-title":"alpha-Synuclein locus duplication as a cause of familial Parkinson's disease","volume":"364","author":"M-C Chartier-Harlin","year":"2004","journal-title":"Lancet"},{"issue":"2","key":"ref7","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/ana.10795","article-title":"The new mutation, E46K, of alpha-synuclein causes parkinson and Lewy body dementia","volume":"55","author":"J Zarranz","year":"2004","journal-title":"Annals of neurology"},{"issue":"2","key":"ref8","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/ng0298-106","article-title":"Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease","volume":"18","author":"R Kruger","year":"1998","journal-title":"Nature genetics"},{"issue":"6645","key":"ref9","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"Alpha-synuclein in Lewy bodies","volume":"388","author":"MG Spillantini","year":"1997","journal-title":"Nature"},{"issue":"6","key":"ref10","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/j.1471-4159.2004.02423.x","article-title":"Could a loss of alpha-synuclein function put dopaminergic neurons at risk?","volume":"89","author":"RG Perez","year":"2004","journal-title":"J Neurochem"},{"key":"ref11","article-title":"The contribution of alpha synuclein to neuronal survival and function\u2014Implications for Parkinson's Disease","author":"MJ Benskey","year":"2016","journal-title":"J Neurochem"},{"issue":"6","key":"ref12","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1096\/fj.03-1112rev","article-title":"Does alpha-synuclein modulate dopaminergic synaptic content and tone at the synapse?","volume":"18","author":"A Sidhu","year":"2004","journal-title":"FASEB journal: official publication of the Federation of American Societies for Experimental Biology"},{"issue":"8","key":"ref13","first-page":"3090","article-title":"A role for alpha-synuclein in the regulation of dopamine biosynthesis. The Journal of neuroscience: the official journal of the","volume":"22","author":"RG Perez","year":"2002","journal-title":"Society for Neuroscience"},{"issue":"Pt 15","key":"ref14","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1242\/jcs.02481","article-title":"Alpha-synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells","volume":"118","author":"X Peng","year":"2005","journal-title":"J Cell Sci"},{"issue":"4","key":"ref15","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/jnc.12481","article-title":"Non-motor parkinsonian pathology in aging A53T alpha-synuclein mice is associated with progressive synucleinopathy and altered enzymatic function","volume":"128","author":"KF Farrell","year":"2014","journal-title":"J Neurochem"},{"issue":"23","key":"ref16","doi-asserted-by":"crossref","first-page":"17648","DOI":"10.1074\/jbc.M110.100867","article-title":"Serine 129 phosphorylation reduces the ability of alpha-synuclein to regulate tyrosine hydroxylase and protein phosphatase 2A in vitro and in vivo","volume":"285","author":"H Lou","year":"2010","journal-title":"J Biol Chem"},{"issue":"7","key":"ref17","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1021\/ml500128g","article-title":"Novel FTY720-based compounds stimulate neurotrophin expression and phosphatase activity in dopaminergic cells","volume":"5","author":"J Vargas-Medrano","year":"2014","journal-title":"ACS Medicinal Chemistry Letters"},{"key":"ref18","first-page":"51","article-title":"Nova Publishers\u2014Alpha-Synuclein","author":"JL Porras","year":"2014"},{"issue":"1","key":"ref19","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.neulet.2008.02.014","article-title":"Alpha-synuclein aggregation alters tyrosine hydroxylase phosphorylation and immunoreactivity: lessons from viral transduction of knockout mice","volume":"435","author":"TN Alerte","year":"2008","journal-title":"Neuroscience letters"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.neuroscience.2012.01.028","article-title":"Lewy-like aggregation of alpha-synuclein reduces protein phosphatase 2A activity in vitro and in vivo","volume":"207","author":"J Wu","year":"2012","journal-title":"Neuroscience"},{"issue":"19","key":"ref21","first-page":"6963","article-title":"Enhanced phosphatase activity attenuates alpha-synucleinopathy in a mouse model. The Journal of neuroscience: the official journal of the","volume":"31","author":"KW Lee","year":"2011","journal-title":"Society for Neuroscience"},{"issue":"1","key":"ref22","first-page":"41","article-title":"Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. The Journal of neuroscience: the official journal of the","volume":"26","author":"LJ Martin","year":"2006","journal-title":"Society for Neuroscience"},{"issue":"5","key":"ref23","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.neurobiolaging.2013.11.008","article-title":"Mitochondrial permeability transition pore regulates Parkinson's disease development in mutant alpha-synuclein transgenic mice","volume":"35","author":"LJ Martin","year":"2014","journal-title":"Neurobiol Aging"},{"issue":"10","key":"ref24","doi-asserted-by":"crossref","first-page":"7334","DOI":"10.1074\/jbc.M109.061051","article-title":"The transgenic overexpression of alpha-synuclein and not its related pathology associates with complex I inhibition","volume":"285","author":"V Loeb","year":"2010","journal-title":"J Biol Chem"},{"issue":"10","key":"ref25","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/j.biocel.2009.05.008","article-title":"Alpha-synuclein overexpression and aggregation exacerbates impairment of mitochondrial functions by augmenting oxidative stress in human neuroblastoma cells","volume":"41","author":"MS Parihar","year":"2009","journal-title":"The international journal of biochemistry & cell biology"},{"issue":"11","key":"ref26","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/ncpneuro0924","article-title":"Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis","volume":"4","author":"C Henchcliffe","year":"2008","journal-title":"Nature clinical practice Neurology"},{"issue":"7","key":"ref27","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.bbadis.2008.11.007","article-title":"Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis","volume":"1792","author":"R Banerjee","year":"2009","journal-title":"Biochimica et biophysica acta"},{"issue":"11","key":"ref28","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1182\/blood-2013-03-492181","article-title":"Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies","volume":"122","author":"JJ Oaks","year":"2013","journal-title":"Blood"},{"issue":"2","key":"ref29","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10555-008-9119-x","article-title":"Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias","volume":"27","author":"D Perrotti","year":"2008","journal-title":"Cancer metastasis reviews"},{"issue":"11","key":"ref30","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/nrd3248","article-title":"Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis","volume":"9","author":"V Brinkmann","year":"2010","journal-title":"Nature reviews Drug discovery"},{"issue":"1","key":"ref31","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4103\/0976-500X.77118","article-title":"Fingolimod (FTY720): First approved oral therapy for multiple sclerosis","volume":"2","author":"S Sharma","year":"2011","journal-title":"Journal of Pharmacology & Pharmacotherapeutics"},{"issue":"1","key":"ref32","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/ana.22186","article-title":"Fingolimod provides long-term protection in rodent models of cerebral ischemia","volume":"69","author":"Y Wei","year":"2011","journal-title":"Annals of neurology"},{"issue":"2","key":"ref33","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.pbb.2012.08.025","article-title":"Fingolimod (FTY720) inhibits neuroinflammation and attenuates spontaneous convulsions in lithium-pilocarpine induced status epilepticus in rat model","volume":"103","author":"F Gao","year":"2012","journal-title":"Pharmacology, biochemistry, and behavior"},{"issue":"9","key":"ref34","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1093\/hmg\/ddt615","article-title":"FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in cellular and mouse models of Huntington disease","volume":"23","author":"A Di Pardo","year":"2014","journal-title":"Human molecular genetics"},{"issue":"1\u20132","key":"ref35","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jneuroim.2012.12.005","article-title":"Fingolimod phosphate promotes the neuroprotective effects of microglia","volume":"256","author":"H Noda","year":"2013","journal-title":"Journal of neuroimmunology"},{"issue":"35","key":"ref36","doi-asserted-by":"crossref","first-page":"14230","DOI":"10.1073\/pnas.1206093109","article-title":"Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome","volume":"109","author":"R Deogracias","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"ref37","doi-asserted-by":"crossref","first-page":"e61988","DOI":"10.1371\/journal.pone.0061988","article-title":"Fingolimod phosphate attenuates oligomeric amyloid beta-induced neurotoxicity via increased brain-derived neurotrophic factor expression in neurons","volume":"8","author":"Y Doi","year":"2013","journal-title":"PLoS One"},{"issue":"7","key":"ref38","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/nn.3728","article-title":"Active, phosphorylated fingolimod inhibits histone deacetylases and facilitates fear extinction memory","volume":"17","author":"NC Hait","year":"2014","journal-title":"Nature neuroscience"},{"issue":"2","key":"ref39","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/bdd.535","article-title":"Oral-intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effects","volume":"28","author":"JM Kovarik","year":"2007","journal-title":"Biopharmaceutics & drug disposition"},{"issue":"4","key":"ref40","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1177\/0091270004274288","article-title":"FTY720 pharmacokinetics in mild to moderate hepatic impairment","volume":"45","author":"JM Kovarik","year":"2005","journal-title":"Journal of clinical pharmacology"},{"issue":"2","key":"ref41","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1124\/dmd.110.035907","article-title":"Absorption and disposition of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in healthy volunteers: a case of xenobiotic biotransformation following endogenous metabolic pathways","volume":"39","author":"M Zollinger","year":"2011","journal-title":"Drug metabolism and disposition: the biological fate of chemicals"},{"issue":"5","key":"ref42","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/j.1365-2125.2003.02065.x","article-title":"Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects","volume":"57","author":"JM Kovarik","year":"2004","journal-title":"British journal of clinical pharmacology"},{"issue":"2","key":"ref43","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S0003-2697(02)00377-9","article-title":"Nonradioactive technique to measure protein phosphatase 2A-like activity and its inhibition by drugs in cell extracts","volume":"310","author":"AR Fathi","year":"2002","journal-title":"Analytical biochemistry"},{"issue":"2","key":"ref44","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1124\/dmd.110.035378","article-title":"CYP4F enzymes are responsible for the elimination of fingolimod (FTY720), a novel treatment of relapsing multiple sclerosis","volume":"39","author":"Y Jin","year":"2011","journal-title":"Drug metabolism and disposition: the biological fate of chemicals"},{"issue":"16","key":"ref45","doi-asserted-by":"crossref","first-page":"5373","DOI":"10.1021\/jm050242f","article-title":"Novel immunomodulator FTY720 is phosphorylated in rats and humans to form a single stereoisomer. Identification, chemical proof, and biological characterization of the biologically active species and its enantiomer","volume":"48","author":"R Albert","year":"2005","journal-title":"Journal of medicinal chemistry"},{"issue":"1\u20132","key":"ref46","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0014-5793(03)01168-2","article-title":"The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2","volume":"554","author":"SW Paugh","year":"2003","journal-title":"FEBS letters"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000264398","article-title":"Blood-brain barrier as a regulatory interface","volume":"63","author":"WA Banks","year":"2010","journal-title":"Forum Nutr"},{"issue":"9","key":"ref48","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1124\/dmd.113.056770","article-title":"Translational pharmacokinetic modeling of fingolimod (FTY720) as a paradigm compound subject to sphingosine kinase-mediated phosphorylation","volume":"42","author":"N Snelder","year":"2014","journal-title":"Drug metabolism and disposition: the biological fate of chemicals"},{"issue":"9","key":"ref49","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1124\/dmd.105.009001","article-title":"Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses","volume":"34","author":"GM Meno-Tetang","year":"2006","journal-title":"Drug metabolism and disposition: the biological fate of chemicals"},{"issue":"6","key":"ref50","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/00007691-200412000-00001","article-title":"Overview of FTY720 clinical pharmacokinetics and pharmacology","volume":"26","author":"JM Kovarik","year":"2004","journal-title":"Therapeutic drug monitoring"},{"issue":"2","key":"ref51","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1042\/bj1040545","article-title":"Lipids of the adrenal medulla: Lysolecithin, a characteristic constituent of chromaffin granules","volume":"104","author":"H Blaschko","year":"1967","journal-title":"Biochemical Journal"},{"issue":"4","key":"ref52","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/j.1471-4159.2006.04146.x","article-title":"Alpha-synuclein inhibits aromatic amino acid decarboxylase activity in dopaminergic cells","volume":"99","author":"R Tehranian","year":"2006","journal-title":"J Neurochem"},{"issue":"8","key":"ref53","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1111\/j.1460-9568.2005.04391.x","article-title":"Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation","volume":"22","author":"F Liu","year":"2005","journal-title":"The European journal of neuroscience"},{"issue":"8","key":"ref54","doi-asserted-by":"crossref","first-page":"5535","DOI":"10.1074\/jbc.275.8.5535","article-title":"Phosphorylation of microtubule-associated protein tau is regulated by protein phosphatase 2A in mammalian brain. Implications for neurofibrillary degeneration in Alzheimer's disease","volume":"275","author":"CX Gong","year":"2000","journal-title":"The Journal of biological chemistry"},{"issue":"13","key":"ref55","doi-asserted-by":"crossref","first-page":"6084","DOI":"10.1016\/S0021-9258(17)38495-8","article-title":"Microtubule-associated protein tau. A component of Alzheimer paired helical filaments","volume":"261","author":"I Grundke-Iqbal","year":"1986","journal-title":"The Journal of biological chemistry"},{"issue":"13","key":"ref56","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.1073\/pnas.83.13.4913","article-title":"Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology","volume":"83","author":"I Grundke-Iqbal","year":"1986","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"8","key":"ref57","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.jocn.2010.04.020","article-title":"Sodium selenate specifically activates PP2A phosphatase, dephosphorylates tau and reverses memory deficits in an Alzheimer's disease model","volume":"17","author":"NM Corcoran","year":"2010","journal-title":"Journal of clinical neuroscience: official journal of the Neurosurgical Society of Australasia"},{"issue":"31","key":"ref58","doi-asserted-by":"crossref","first-page":"13888","DOI":"10.1073\/pnas.1009038107","article-title":"Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models","volume":"107","author":"J van Eersel","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"ref59","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa052643","article-title":"Oral fingolimod (FTY720) for relapsing multiple sclerosis","volume":"355","author":"L Kappos","year":"2006","journal-title":"The New England journal of medicine"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1146\/annurev.immunol.23.021704.115707","article-title":"Immunology of multiple sclerosis","volume":"23","author":"M Sospedra","year":"2005","journal-title":"Annual review of immunology"},{"issue":"7","key":"ref61","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1084\/jem.20091343","article-title":"Cell-surface residence of sphingosine 1-phosphate receptor 1 on lymphocytes determines lymphocyte egress kinetics","volume":"207","author":"S Thangada","year":"2010","journal-title":"The Journal of experimental medicine"},{"issue":"24","key":"ref62","doi-asserted-by":"crossref","first-page":"21453","DOI":"10.1074\/jbc.C200176200","article-title":"The immune modulator FTY720 targets sphingosine 1-phosphate receptors","volume":"277","author":"V Brinkmann","year":"2002","journal-title":"J Biol Chem"},{"issue":"48","key":"ref63","doi-asserted-by":"crossref","first-page":"47408","DOI":"10.1074\/jbc.M307687200","article-title":"Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases","volume":"278","author":"A Billich","year":"2003","journal-title":"J Biol Chem"},{"issue":"6972","key":"ref64","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nature02284","article-title":"Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1","volume":"427","author":"M Matloubian","year":"2004","journal-title":"Nature"},{"key":"ref65","article-title":"Prism Version 5.0 Statistics Guide. Prism","author":"HJ Motulsky","year":"2007"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0162162","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T01:44:08Z","timestamp":1657244648000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0162162"}},"subtitle":[],"editor":[{"given":"Jonghan","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,9,9]]},"references-count":65,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2016,9,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0162162","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,9]]}}}